World's Best Scientists 2026 revealed!
Award Badge
Medicine
Switzerland
2023

D-Index & Metrics

Medicine

D-Index
149
Citations
104924
World Ranking
1182
National Ranking
686

Jeffrey A. Engelman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jeffrey A. Engelman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 377 publications — 33rd percentile

33% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jeffrey A. Engelman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jeffrey A. Engelman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 149 D-Index — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Switzerland Leader Award

Overview

Jeffrey A. Engelman is affiliated with the Novartis Institutes for BioMedical Research (NIBR) in the United States. Their research spans key areas within biochemistry, genetics, molecular biology, and medicine, with a focus on understanding molecular mechanisms relevant to cancer biology.

Their work is primarily concentrated in several subfields including molecular biology, oncology, pulmonary and respiratory medicine, cancer research, and pathology and forensic medicine. Within these subfields, Engelman's research addresses topics such as lung cancer treatments and mutations, cancer genomics and diagnostics, protein tyrosine phosphatases, cancer cells and metastasis, protein degradation and inhibitors, cancer mechanisms and therapy, and computational drug discovery methods.

Engelman has published multiple papers, with notable recent publications including:

  • Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms (2021) published in Cancer Cell
  • The present and future of PI3K inhibitors for cancer therapy (2021) in Nature Cancer
  • TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts (2020) in Nature Communications
  • Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling (2020) in Clinical Cancer Research
  • Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy (2023) in Cell chemical biology

Frequent co-authors collaborating with Engelman include:

  • Cyril H. Benes
  • David A. Ruddy
  • Peter S. Hammerman
  • Giordano Caponigro
  • Joel P. Wagner

Engelman's research outputs have appeared predominantly in the following publication venues:

  • UNC Libraries
  • Cancer Research
  • Nature Communications
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Cancer Research

Best Publications

  • MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Tetsuya Mitsudomi;Youngchul Song

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

    Jeffrey A. Engelman;Ji Luo;Lewis C. Cantley

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

    Jeffrey A. Engelman

  • Systematic identification of genomic markers of drug sensitivity in cancer cells

    Mathew J. Garnett;Elena J. Edelman;Sonja J. Heidorn;Christopher Greenman;Christopher Greenman

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

    Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Grit S. Herter-Sprie

  • Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

    Jeffrey A. Engelman;Jeffrey A. Engelman;Liang Chen;Xiaohong Tan;Katherine Crosby

  • Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

    Vasanthi S. Viswanathan;Matthew J. Ryan;Harshil D. Dhruv;Shubhroz Gill

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    Ryohei Katayama;Alice T. Shaw;Alice T. Shaw;Tahsin M. Khan;Tahsin M. Khan;Mari Mino-Kenudson

  • Caveolins, liquid-ordered domains, and signal transduction.

    Eric J. Smart;Gregory A. Graf;Mark A. McNiven;William C. Sessa

  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  • EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

    Jussi P. Koivunen;Craig Mermel;Kreshnik Zejnullahu;Carly Murphy

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

    Carlos L. Arteaga;Jeffrey A. Engelman

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

    Justin F. Gainor;Alice T. Shaw;Lecia V. Sequist;Xiujun Fu

Frequent Co-Authors

Alice T. Shaw
Alice T. Shaw Harvard University
Lecia V. Sequist
Lecia V. Sequist Harvard University
Pasi A. Jänne
Pasi A. Jänne Harvard University
Mari Mino-Kenudson
Mari Mino-Kenudson Harvard University
Cyril H. Benes
Cyril H. Benes Harvard University
Justin F. Gainor
Justin F. Gainor Harvard University
Kwok-Kin Wong
Kwok-Kin Wong New York University
A. John Iafrate
A. John Iafrate Harvard University
Lewis C. Cantley
Lewis C. Cantley Harvard University
Jeffrey Settleman
Jeffrey Settleman Pfizer (Germany)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider studying Medicine in the USA, it’s valuable to look at related online degrees and flexible career pathways in healthcare. Many students and working professionals are drawn to accelerated healthcare programs that allow for a quicker route into administrative or clinical roles.

Registered nurses interested in leadership or advanced practice should explore adn to msn bridge programs. These programs let RNs move efficiently from an associate degree to a master’s degree, expanding their career options in less time.

If you are passionate about nutrition and preventive health, an online nutrition degree can open doors in clinical, research, or wellness fields. For working adults seeking leadership roles, finding whats the best online mha program for working adults is key to gaining advanced management skills without pausing your current career.

Each of these online pathways provides flexibility, supports work-life balance, and offers opportunities for professional growth within the rapidly evolving healthcare sector.

Best Scientists Citing Jeffrey A. Engelman

Trending Scientists

Recently Published Articles